Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PALIPERIDONE Cause Product temperature excursion issue? 8 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Product temperature excursion issue have been filed in association with PALIPERIDONE (paliperidone). This represents 0.0% of all adverse event reports for PALIPERIDONE.

8
Reports of Product temperature excursion issue with PALIPERIDONE
0.0%
of all PALIPERIDONE reports
0
Deaths
1
Hospitalizations

How Dangerous Is Product temperature excursion issue From PALIPERIDONE?

Of the 8 reports, 1 (12.5%) required hospitalization.

Is Product temperature excursion issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PALIPERIDONE. However, 8 reports have been filed with the FAERS database.

What Other Side Effects Does PALIPERIDONE Cause?

Injury (4,348) Gynaecomastia (4,155) Off label use (4,041) Drug ineffective (2,812) Weight increased (2,136) Hospitalisation (2,066) Abnormal weight gain (1,816) Hyperprolactinaemia (1,427) Schizophrenia (1,361) Product dose omission issue (1,304)

What Other Drugs Cause Product temperature excursion issue?

SECUKINUMAB (219) ADALIMUMAB (190) ABATACEPT (158) OFATUMUMAB (157) INSULIN GLARGINE (130) TOCILIZUMAB (129) VEDOLIZUMAB (111) ONABOTULINUMTOXINA (96) BRENTUXIMAB VEDOTIN (94) RISANKIZUMAB (88)

Which PALIPERIDONE Alternatives Have Lower Product temperature excursion issue Risk?

PALIPERIDONE vs PALIVIZUMAB PALIPERIDONE vs PALONOSETRON PALIPERIDONE vs PAMIDRONATE PALIPERIDONE vs PAMIDRONIC ACID PALIPERIDONE vs PANCRELIPASE

Related Pages

PALIPERIDONE Full Profile All Product temperature excursion issue Reports All Drugs Causing Product temperature excursion issue PALIPERIDONE Demographics